Privately held company located in Southern California. NuvoLase acquired certain rights, assets and intellectual properties associated with the PinPointe™ FootLaser®. NuvoLase is actively engaged in future product development based on the unmet needs of clinicians and patients worldwide.
PinPointe™ FootLaser®, NuvoLase’s first and flagship product is the first light-based device to receive FDA clearance for Onycomycosis treatment, and is recognized by industry leaders as the gold standard product and alternative procedure for those patients suffering from Onychomycosis. Regulatory clearances for the PinPointe™ FootLaser® include FDA clearances, and CE Mark
All NuvoLase products provide superior clinical performance and the result of solid research, sound science, and clinical studies.